drugset / Trial / NCT05422001
Low-dose KETamine as an Adjunct to MOrphine for Acute Pain in the ED
Phase 4
Terminated
116 enrolled
University of Aarhus
Aarhus University Hospital · collabCentral Denmark Region · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The KetMo study is an investigator-initiated, randomized, parallel group, double blinded trial investigating if ketamine as an adjunct to morphine improves pain treatment in the ED. Patients in pain (assessed on NRS, 5 or more) will be randomized to low-dose ketamine or placebo as an adjunct to morphine. Patients with or without prior use of opioids will be randomized separately. The primary outcome will be pain reduction, assessed on NRS, after 10 minutes. Secondary outcomes include pain reduction until 120 minutes after injection of study medicine, need for rescue opioid, side effects and patient- and provider satisfaction.
Timeline
- Start
- 2022-05-31
- Primary completion
- 2023-08-15
- Completion
- 2023-08-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Esketamine | Other / unclassified | 0.1 mg/kg | Intravenous |